| 臺大學術典藏 |
2022-09-21T23:32:19Z |
B Cells in Tumor Microenvironment Associated With The Clinical Benefit to Programmed Cell Death Protein-1 Blockade Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma
|
JHE-CYUAN GUO; CHIA-LANG HSU; YEN-LIN HUANG; Chia-Chi Lin; TA-CHEN HUANG; Wu, I. Chen; Lin, Chen Yuan; Lien, Ming Yu; HUNG-YANG KUO; ANN-LII CHENG; CHIH-HUNG HSU |
| 臺大學術典藏 |
2022-09-21T23:32:18Z |
Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinoma
|
JHE-CYUAN GUO; Chia-Chi Lin; CHIA-LANG HSU; TA-CHEN HUANG; HUNG-YANG KUO; Lin, Chen Yuan; Lien, Ming Yu; ANN-LII CHENG; CHIH-HUNG HSU |
| 臺大學術典藏 |
2022-03-14T23:45:18Z |
Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma
|
YU-YUN SHAO; Chen, Pai Sheng; LIANG-IN LIN; Lee, Bin Shyun; Ling, Andrew; ANN-LII CHENG; CHIUN HSU; DA-LIANG OU |
| 臺大學術典藏 |
2022-03-14T23:44:59Z |
Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma
|
YU-YUN SHAO; HUNG-YANG KUO; YUNG-MING JENG; YAO-MING WU; HSIU-PO WANG; CHIUN HSU; CHIH-HUNG HSU; Hsu, Hey Chi; ANN-LII CHENG; Lin, Zhong Zhe |
| 臺大學術典藏 |
2022-03-14T23:44:59Z |
Current Status of the Spectrum and Therapeutics of Helicobacter pylori-Negative Mucosa-Associated Lymphoid Tissue Lymphoma
|
SUNG-HSIN KUO; KUN-HUEI YEH; CHUNG-WU LIN; JYH-MING LIOU; MING-SHIANG WU; Chen, Li Tzong; ANN-LII CHENG |
| 臺大學術典藏 |
2022-02-21T02:04:36Z |
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
|
Ou D.-L.; Chen C.-W.; Hsu C.-L.; Chung C.-H.; Feng Z.-R.; Lee B.-S.; ANN-LII CHENG; Yang M.-H.; Hsu C. |
| 臺大學術典藏 |
2022-02-21T02:04:36Z |
Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy
|
Huang T.-C.; Liang C.-W.; Li Y.-I.; Guo J.-C.; Lin C.-C.; Chen Y.-J.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
|
Hsu C.-L.; Ou D.-L.; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; ANN-LII CHENG; Jeng Y.-M.; Hsu C. |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
|
Qin S.; Ren Z.; Feng Y.-H.; Yau T.; Wang B.; Zhao H.; Bai Y.; Gu S.; Li L.; Hernandez S.; Xu D.-Z.; Mulla S.; Wang Y.; Shao H.; ANN-LII CHENG |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT
|
Okusaka T.; Ikeda K.; Kudo M.; Finn R.; Qin S.; Han K.-H.; ANN-LII CHENG; Piscaglia F.; Kobayashi M.; Sung M.; Chen M.; Wyrwicz L.; Yoon J.-H.; Ren Z.; Mody K.; Dutcus C.; Tamai T.; Ren M.; Hayato S.; Kumada H. |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: A subgroup analysis of asian patients in the phase 3 KEYNOTE-240 trial
|
Kudo M.; Lim H.Y.; ANN-LII CHENG; Chao Y.; Yau T.; Ogasawara S.; Kurosaki M.; Morimoto N.; Ohkawa K.; Yamashita T.; Lee K.-H.; Chen E.; Siegel A.B.; Ryoo B.-Y. |
| 臺大學術典藏 |
2022-02-21T02:04:34Z |
Eg5 as a prognostic biomarker and potential therapeutic target for hepatocellular carcinoma
|
Shao Y.-Y.; Sun N.-Y.; Jeng Y.-M.; Wu Y.-M.; Hsu C.; Hsu C.-H.; Hsu H.-C.; ANN-LII CHENG; Lin Z.-Z. |
| 臺大學術典藏 |
2022-02-21T02:04:34Z |
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
|
Galle P.R.; Finn R.S.; Qin S.; Ikeda M.; Zhu A.X.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.; Li D.; Mulla S.; Verret W.; Xu D.-Z.; Hernandez S.; Ding B.; Liu J.; Huang C.; Lim H.Y.; ANN-LII CHENG; Ducreux M. |
| 臺大學術典藏 |
2022-02-21T02:04:33Z |
Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma
|
Chen B.-B.; Shao Y.-Y.; Lin Z.-Z.; Hsu C.-H.; ANN-LII CHENG; Hsu C.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-02-21T02:04:33Z |
Evolution of systemic treatment for advanced hepatocellular carcinoma
|
Wu T.-C.; Shen Y.-C.; ANN-LII CHENG |
| 臺大學術典藏 |
2022-02-21T02:04:33Z |
Association between risk factors, molecular features and CpG island methylator phenotype colorectal cancer among different age groups in a Taiwanese cohort
|
Chen K.-H.; Lin L.-I.; Yuan C.-T.; Tseng L.-H.; Chao Y.-L.; Liang Y.-H.; Liang J.-T.; Lin B.-R.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2022-02-21T02:04:32Z |
Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
|
Chen I.-C.; Hu F.-C.; Lin C.-H.; Huang S.-M.; Chang D.-Y.; ANN-LII CHENG; Lu Y.-S. |
| 臺大學術典藏 |
2022-02-21T02:04:32Z |
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
|
Greten T.F.; Abou-Alfa G.K.; ANN-LII CHENG; Duffy A.G.; El-Khoueiry A.B.; Finn R.S.; Galle P.R.; Goyal L.; He A.R.; Kaseb A.O.; Kelley R.K.; Lencioni R.; Lujambio A.; Mabry Hrones D.; Pinato D.J.; Sangro B.; Troisi R.I.; Wilson Woods A.; Yau T.; Zhu A.X.; Melero I. |
| 臺大學術典藏 |
2022-02-21T02:04:32Z |
Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: From the phase III REFLECT study
|
Finn R.S.; Kudo M.; ANN-LII CHENG; Wyrwicz L.; Ngan R.K.C.; Blanc J.-F.; Baron A.D.; Vogel A.; Ikeda M.; Piscaglia F.; Han K.-H.; Qin S.; Minoshima Y.; Kanekiyo M.; Ren M.; Dairiki R.; Tamai T.; Dutcus C.E.; Ikezawa H.; Funahashi Y.; Evans T.R.J. |
| 臺大學術典藏 |
2022-02-21T02:04:31Z |
Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-�eB-related signaling
|
Kuo S.-H.; Yang S.-H.; Wei M.-F.; Lee H.-W.; Tien Y.-W.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2022-02-21T02:04:31Z |
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy
|
Lau G.; Yu M.-L.; Wong G.; Thompson A.; Ghazinian H.; Hou J.-L.; Piratvisuth T.; Jia J.-D.; Mizokami M.; Cheng G.; Chen G.-F.; Liu Z.-W.; Baatarkhuu O.; ANN-LII CHENG; Ng W.L.; Lau P.; Mok T.; Chang J.-M.; Hamid S.; Dokmeci A.K.; Gani R.A.; Payawal D.A.; Chow P.; Park J.-W.; Strasser S.I.; Mohamed R.; Win K.M.; Tawesak T.; Sarin S.K.; Omata M. |
| 臺大學術典藏 |
2022-02-21T02:04:29Z |
High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia
|
Lin C.-H.; Huang R.Y.-J.; Lu T.-P.; Kuo K.-T.; Lo K.-Y.; Chen C.-H.; Chen I.-C.; Lu Y.-S.; Chuang E.Y.; Thiery J.P.; Huang C.-S.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-10-21T23:27:09Z |
Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma
|
SHIH-HUNG YANG; Lu, Li Chun; HSIANG-FONG KAO; BANG-BIN CHEN; TING-CHUN KUO; SUNG-HSIN KUO; YU-WEN TIEN; Bai, Li Yuan; ANN-LII CHENG; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-09-14T23:19:03Z |
High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia
|
CHING-HUNG LIN; RUBY YUN-JU HUANG; TZU-PIN LU; KUAN-TING KUO; Lo, Ko Yun; Chen, Ching Hsuan; Chen, I. Chun; YEN-SHEN LU; Chuang, Eric Y.; Thiery, Jean Paul; CHIUN-SHENG HUANG; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-14T23:18:53Z |
Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy
|
Huang, Ta Chen; Liang, Cher Wei; YU-I LI; Guo, Jhe Cyuan; Chia-Chi Lin; Chen, Ya Jhen; ANN-LII CHENG; CHIH-HUNG HSU |
| 臺大學術典藏 |
2021-09-14T23:18:31Z |
Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-κB-related signaling
|
SUNG-HSIN KUO; SHIH-HUNG YANG; Wei, Ming Feng; Lee, Hsiao Wei; YU-WEN TIEN; ANN-LII CHENG; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-09-14T23:18:28Z |
Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma
|
YU-YUN SHAO; Sun, Nai Yun; YUNG-MING JENG; YAO-MING WU; CHIUN HSU; CHIH-HUNG HSU; Hsu, Hey Chi; ANN-LII CHENG; Lin, Zhong Zhe |
| 臺大學術典藏 |
2021-09-01T02:02:52Z |
Allogeneic bone marrow transplantation in the treatment of leukemia--a preliminary report
|
Chen Y.C.; Wang C.H.; Lin D.T.; Lui P.T.; ANN-LII CHENG; Liu T.W.; Tsay W.; Tien H.F.; Liu M.C.; Chuu W.M. |
| 臺大學術典藏 |
2021-09-01T02:02:52Z |
Adult acute lymphoblastic leukemia--lineage specific classification of 30 cases.
|
ANN-LII CHENG; Chen Y.C.; Wang C.H.; Shen M.C.; Hsieh R.P.; Tien H.F.; Liu M.C.; Lai H.S.; Liu C.H. |
| 臺大學術典藏 |
2021-09-01T02:02:51Z |
Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades - Should peripheral T-cell lymphoma be considered separately?
|
ANN-LII CHENG; Chen Y.-C.; Wang C.-H.; Su I.-J.; Hsieh H.-C.; Chang J.-Y.; Hwang W.-S.; Su W.-C.; Liu T.-W.; Tien H.-F.; Tsai W.; Shen M.-C.; Liu C.-H. |
| 臺大學術典藏 |
2021-09-01T02:02:51Z |
Characterization of the spectrum of postthymic T?cell malignancies in Taiwan a clinicopathologic study of HTLV?1?positive and HTLV?1?negative cases
|
Su I.J.; Wang C.H.; ANN-LII CHENG; Chen Y.C.; Hsieh H.C.; Tien H.F.; Huang S.S.; Hu C.Y.; Chen P.J.; Chen J.Y.; Hsu H.C.; Chuang S.M.; Shen M.C.; Kadin M.E. |
| 臺大學術典藏 |
2021-09-01T02:02:51Z |
Adult non-Hodgkin's lymphoma in Taiwan area: A clinicopathologic study of 123 cases based on working formulation classification
|
ANN-LII CHENG; Chen Y.-C.; Su I.-J.; Wang C.-H.; Hsieh H.-C.; Chen C.-L.; Lai H.-S.; Liu T.-W.; Tien H.-F.; Shen M.-C.; Liu C.-H. |
| 臺大學術典藏 |
2021-09-01T02:02:50Z |
Cutaneous manifestations of postthymic T cell malignancies: Description of five clinicopathologic subtypes
|
Su I.-J.; Wu Y.-C.; Chen Y.-C.; Hsieh H.-C.; ANN-LII CHENG; Wang C.-H.; Kadin M.E. |
| 臺大學術典藏 |
2021-09-01T02:02:50Z |
Bone marrow involvement in non-Hodgkin's lymphoma.
|
Lai H.S.; Tien H.F.; Hsieh H.C.; Chen Y.C.; Su I.J.; Wang C.H.; Liu M.C.; ANN-LII CHENG; Shen M.C.; Liu C.H. |
| 臺大學術典藏 |
2021-09-01T02:02:50Z |
13?cis?retinoic acid induces cellular differentiation and durable remission in refractory cutaneous ki?1 lymphoma
|
Chow J.M.; ANN-LII CHENG; Su I.J.; Wang C.H. |
| 臺大學術典藏 |
2021-09-01T02:02:49Z |
Menadione: Spectrum of anticancer activity and effects on nucleotide metabolism in human neoplastic cell lines
|
Nutter L.M.; ANN-LII CHENG; Hsiao-Ling H.; Ruey-Kun H.; Ngo E.O.; Tsang-Wu L. |
| 臺大學術典藏 |
2021-09-01T02:02:49Z |
Disruption of Cellular Energy Balance by Suramin in Intact Human Prostatic Carcinoma Cells, a Likely Antiproliferative Mechanism
|
Rago R.; Mitchen J.; ANN-LII CHENG; Oberley T.; Wilding G. |
| 臺大學術典藏 |
2021-09-01T02:02:49Z |
Aggressive peripheral T-cell lymphomas containing Epstein-Barr viral DNA: A clinicopathologic and molecular analysis
|
Su I.-J.; Hsieh H.-C.; Lin K.-H.; Uen W.-C.; Kao C.-L.; Chen C.-J.; ANN-LII CHENG; Kadin M.E.; Chen J.-Y. |
| 臺大學術典藏 |
2021-09-01T02:02:49Z |
Expression of growth-related genes and drug-resistance genes in HTLV-I-positive and HTLV-I-negative post-thymic T-cell malignancies
|
Su I.-J.; Chang I.-C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:48Z |
Retinoic acid?induced apoptosis and regression of a refractory Epstein?Barr virus?containing T cell lymphoma expressing multidrug?resistance phenotypes
|
Su I.J.; ANN-LII CHENG; Tsai T.F.; Lay J.D. |
| 臺大學術典藏 |
2021-09-01T02:02:48Z |
Present status of cancer treatment in Taiwan
|
How S.-W.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:48Z |
Cutaneous angiocentric T-cell lymphoma associated with Epstein-Barr virus
|
Tsai T.-F.; Su I.-J.; Lu Y.-C.; ANN-LII CHENG; Yeh H.-P.; Hsieh H.-C.; Tien H.-F.; Chen J.-S.; Uen W.-C. |
| 臺大學術典藏 |
2021-09-01T02:02:48Z |
Menadione-induced DNA damage in a human tumor cell line
|
Ngo E.O.; Sun T.-P.; Chang J.-Y.; Wang C.-C.; Chi K.-H.; ANN-LII CHENG; Nutter L.M. |
| 臺大學術典藏 |
2021-09-01T02:02:47Z |
Characteristic clinicopathologic features of adult B?cell lymphoblastic lymphoma with special emphasis on differential diagnosis with an atypical form probably of blastic lymphocytic lymphoma of intermediate differentiation origin
|
ANN-LII CHENG; Su I.?J.; Tien H.F.; Wang C.C.; Chen Y.C.; Wang C.H. |
| 臺大學術典藏 |
2021-09-01T02:02:47Z |
Cutaneous manifestations of Epstein-Barr virus—associated T-cell lymphoma
|
Su I.-J.; Tsai T.-F.; ANN-LII CHENG; Chen C.-C. |
| 臺大學術典藏 |
2021-09-01T02:02:47Z |
Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: The possible role of epstein-barr virus, immunophenotypes, and other predisposing factors
|
ANN-LII CHENG; Su I.-J.; Chen Y.-C.; Lee T.-C.; Wang C.-H. |
| 臺大學術典藏 |
2021-09-01T02:02:47Z |
Epstein—barr virus?containing t?cell lymphoma presents with hemophagocytic syndrome mimicking malignant histiocytosis
|
Su I.J.; Hsu Y.H.; Lin M.T.; ANN-LII CHENG; Wang C.H.; Weiss L.M. |
| 臺大學術典藏 |
2021-09-01T02:02:47Z |
Characteristic clinicopathologic features of epstein?barr virus—associated peripheral T?cell lymphoma
|
ANN-LII CHENG; Su I.J.; Chen Y.C.; Uen W.C.; Wang C.H. |
| 臺大學術典藏 |
2021-09-01T02:02:46Z |
Use of retinoic acids in the treatment of peripheral T-cell lymphoma: A pilot study
|
ANN-LII CHENG; Su I.-J.; Chen C.-C.; Tien H.-F.; Lay J.-D.; Chen B.-R.; Pu Y.-S.; Hong R.-L.; Shen M.-C.; Wang C.-H.; Chen Y.-C. |
| 臺大學術典藏 |
2021-09-01T02:02:46Z |
Modulation of retinoic acid receptor alpha, growth factor and proto-oncogenes in retinoic acid-induced apoptosis of Ki-1 lymphoma cell line
|
Su I.-J.; Lay Z.-D.; ANN-LII CHENG; Chang Y.-C. |
